



# Silva Pharmaceuticals Limited

সিলভা ফার্মাসিউটিক্যালস লিমিটেড  
Ref: SPL/SD/2025/166

Date: December 30, 2025

## 1. The Chairman

Bangladesh Securities and  
Exchange Commission (BSEC),  
Dhaka.

## 2. Managing Director

Dhaka Stock Exchange  
PLC (DSE), Dhaka-1229

## 3. Managing Director

Chittagong Stock Exchange  
PLC (CSE), Chittagong

### Subject: Price Sensitive Information regarding IPO Fund Utilization.

Dear Sir,

We are pleased to inform you that the 9<sup>th</sup> **Extraordinary General Meeting** of Silva Pharmaceuticals Limited held on Tuesday, 30<sup>th</sup> December, 2025 at 10:30 AM via a hybrid platform, have approved the following resolutions. The resolutions were passed by more than the requisite 51% of the public shareholders, other than sponsors and directors in compliance with Condition No. 6 of Part-C of the Bangladesh Securities and Exchange Commission (BSEC) Consent Letter No. BSEC/CI/IPO-269/2017/429 dated June 28, 2018.

### 1. Ratification of the post-facto revisions to the new factory project.

The shareholders ratified and confirmed the post-facto revisions to the new factory project, undertaken by utilizing IPO proceeds. The key changes, implemented to ensure full compliance with current Good Manufacturing Practices (cGMP) and Directorate General of Drug Administration (DGDA) standards, are:

- Modification of the factory design from a two-storied civil construction to a pre-fabricated steel structure, with the total built-up area increased to **45,848.02 square feet** (including the utility building) from the originally proposed **20,000 square feet; and**
- Procurement and installation of additional machinery and equipment (Like 1. Stability Chamber Equipment, 2. Bin Blender, 3. Coating Machine, 4. Refractometer, 5. Granulation Line, 6. Thin Layer Chromatography, 7. Leveling Machine and 8. Vacuum Drying Oven and others) beyond those specified in the Company's Prospectus.

### 2. Revised Utilization of Unutilized IPO Proceeds and Post-Facto Ratification.

The shareholders approved the revised utilization of unutilized IPO funds and granted post-facto ratification for the use of accrued profits, as follows:

- **Reallocation of Funds:** The unutilized IPO principal amounting to **BDT 2,81,82,638.00 (Taka Two Crore Eighty-One Lakh Eighty-Two Thousand Six Hundred Thirty-Eight Only)**, together with any remaining accrued profit up to the date of transfer, is hereby reallocated from the original head of "**Machinery & Equipment**" to "**Working Capital Requirement**". These funds are to be utilized for the procurement of raw materials and other essential operational expenditures; **and**
- **Post-Facto Ratification of Accrued Profit Utilization:** The utilization of accrued profit generated from the IPO proceeds, totaling **BDT 90,30,327.00 (Ninety Lakh Thirty Thousand Three Hundred Twenty-Seven Taka Only)**, is ratified and confirmed for the following purposes:
  - **BDT 24,74,124.00 (Twenty-Four Lakh Seventy-Four Thousand One Hundred Twenty-Four Taka Only)** utilized for construction of the new factory building; and
  - **BDT 65,56,203.00 (Sixty-Five Lakh Fifty-Six Thousand Two Hundred Three Taka Only)** utilized for working capital purposes.

This is for your kind information and record.

Thanking you

Yours Sincerely,

  
**Md. Iqbal Hossain**  
Company Secretary

